In the dynamic realm of molecular biology, the quest for enhancing diagnostic tools and therapeutic approaches is an ever-evolving journey. One significant breakthrough in this pursuit is the development of the Neomer library, an innovative platform that allows the utilization of identical sequences across various targets. This breakthrough has propelled researchers to delve into a comprehensive characterization of structures within the Neomer library, paving the way for a profound understanding and manipulation of aptamers.
The Neomer Library and Aptamer Structures:
The Neomer library’s groundbreaking feature lies in its ability to deploy the same starting naïve sequences across different targets. This unique characteristic has motivated NeoVentures to invest significant efforts into characterizing the structures within the library comprehensively. The exhaustive endeavor has now yielded a wealth of knowledge, positioning us to delve deeper into the intricacies of these structures immediately after the selection process.
Similar to antibodies, aptamers derive their functionality from the intricate secondary structures they form. In the case of antibodies, these structures are dictated by the sequence and identity of amino acids in the hypervariable regions. Aptamers, on the other hand, rely on the sequence and identity of nucleotides in their hypervariable regions. The detailed understanding of these structures within the Neomer library has set the stage for a transformative approach to aptamer design and improvement.
Building a Knowledge Base for Strategic Design:
Armed with a comprehensive knowledge base of all possible structures within the Neomer library, we can now assess the nature of structures bound by any given target. The meta-analysis capabilities across this expansive database enable us to formulate hypotheses about ideal structures and strategically design them. This in-silico approach to aptamer improvement mirrors the evolutionary principles found in nature.
Emulating Nature’s Strategy:
Nature has perfected the immune system’s ability to screen foreign entities using a relatively small repertoire of naïve antibodies. The selected antibodies undergo recombination to evolve and produce structures with higher binding affinity. Similarly, the Neomer library, with its closed sequence design, enables an in-silico approach to immune tolerance. By defining all structures within the library, we have introduced a parallel in-silico approach to aptamer enhancement, following nature’s time-tested strategy.
Partnering for the Future:
The implications of these advancements extend beyond the laboratory, as more diagnostic companies join forces to pioneer the next wave of applications in healthcare. Collaborations with these forward-thinking entities are crucial for translating research breakthroughs into real-world solutions.
We invite you to explore the possibilities and join the revolution in diagnostic applications. Contact us for a free consultation, where we aim to understand your vision and collaborate to turn it into reality. Together, we can shape the future of molecular diagnostics and therapeutic interventions.
Le Dr. Gregory Penner a suivi une formation académique qui mêlait une théorie très pratique en matière de sélection végétale à la biologie moléculaire. Il a utilisé cette combinaison de biologie et de mathématiques pour développer et diriger une équipe de recherche en biotechnologie céréalière au sein du gouvernement du Canada, puis en tant que leader mondial de la recherche chez Monsanto Inc. Il a été un leader d'opinion en développement d'aptamères à l'échelle mondiale au cours des vingt dernières années en tant que PDG et président de NeoVentures. Il a dirigé cette entreprise vers la stabilité financière sans investissement extérieur grâce à une approche intégrée de la découverte et de la commercialisation des aptamères. En 2015, il a co-fondé une deuxième entreprise, NeoNeuro à Paris en France, axée sur une approche innovante pour identifier les Aptamarkers pour les maladies complexes.
Connectez-vous avec le Dr. Penner sur LinkedIn ou pour les mises à jour de l'entreprise, suivez NeoVentures.
French 
English 
Spanish